Myrexis to Provide Update on the Company's Cancer Metabolism Inhibitor at Upcoming Scientific Meetings
16 sept. 2010 11h31 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 16, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Reports Fiscal Year 2010 Results
09 sept. 2010 16h02 HE
|
Myrexis, Inc.
Robust Oncology Pipeline Advancing
Conference Call Today at 4:30pm ET
Upcoming Events
Announce final Phase 1 data for MPC-3100, a fully-synthetic Hsp90 inhibitor, in solid and hematological...
Myrexis to Present at Rodman & Renshaw and UBS Conferences
02 sept. 2010 09h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Hold Conference Call to Discuss Fiscal Year 2010 Results
31 août 2010 17h06 HE
|
Myrexis, Inc.
SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc. Effective July 1, 2010
30 juin 2010 18h23 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 30, 2010 (GLOBE NEWSWIRE) -- Effective July 1, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) will change its name to Myrexis, Inc. The name change was previously approved by...
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
08 juin 2010 08h50 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 8, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to...
Myriad Pharmaceuticals Announces Presentations of Phase 2 Data of Azixa(TM) Demonstrating Durable Responses in Patients With Glioblastoma Multiforme and Metastatic Melanoma at ASCO 2010
07 juin 2010 08h50 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 7, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of clinical data from two separate Phase 2a combination drug studies of...
Myriad Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
26 mai 2010 12h30 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 26, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the...
Myriad Pharmaceuticals Announces Presentations at 2010 ASCO Annual Meeting
20 mai 2010 18h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that it will be reporting data on its lead oncology candidate, Azixa™ (MPC-6827),...
Myriad Pharmaceuticals Reports Third Quarter FY' 2010 Financial Results
17 mai 2010 16h18 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 17, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2010. The Company ended the...